You just read:

Heptares Announces Positive Results from Phase 1b Clinical Trial with HTL9936, a First-in-class Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Dementia and Schizophrenia

News provided by

Heptares Therapeutics

10 Feb, 2016, 06:30 GMT